title: [Epilepsy in pregnancy].
abstract: Most women with epilepsy will need to continue antiepileptic drugs prior to and during pregnancy. Pre-conception counseling should be available to all wormen with epilepsy who are considering pregnancy, and should address obstetrical complications, change in seizure frequency, and adverse pregnancy outcome. Supplementation with folic acid. 0.4-5 mg/day, is recommended for all women with epilepsy of childbearing potential, especially 3 months prior to conception and throughout the first trimester. It is advisable to obtain serum drug concentrations before pregnancy, when seizure control is optimal, in order to establish a baseline. Serum concentration should be performed each trimester among patients with good seizure control, and monthly in patients with complicated epilepsy, breakthrough seizures, significant side effects, and those treated with lamotrigine or oxcarbazepine. The incidence of major congenital malformations in offspring of women treated with antiepileptic drugs has ranged from 4 to 10%, corresponding to a two-fold increase from the expected incidence in the general population. Malformation rates are higher with valproate, lower with carbamazepine and lamotrigine, and dose-effect relationship has been shown for teratogenicity especially with valproate. An expert morphological assessment, targeted at the neural axis, heart and face, should be performed at 11-13 weeks and 18-22 weeks. There is generally no contraindication to breast feeding among mothers with epilepsy, but further studies are needed to establish the safety of newer antiepileptic drugs.
authors.affiliation: EEG and Epilepsy Unit, Department of Neurology, Assaf Harofeh Medical Center, Zerifin. revitalgm@hotmail.com
authors.forename: Revital
authors.initials: R
authors.lastname: Gandelman-Marton
authors.forename: Miri
authors.initials: M
authors.lastname: Neufeld
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001942:Breast Feeding; D003376:Counseling / Q000379:methods; D016903:Drug Monitoring; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D016742:Preconception Care / Q000379:methods; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome
chemical_list: D000927:Anticonvulsants; D005492:Folic Acid